| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | Chief Accounting Officer | Stock Options (Right to buy) | 17,000 | $328,950 | $19.35 | 02 Feb 2023 | Direct |
| Syndax Pharmaceuticals Inc | Chief Accounting Officer | Common Stock | 0 | $18.27 | 01 Feb 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ONCR | Oncorus, Inc. | 09 May 2023 | 0 | $0 | 3 | Interim CFO | 22 May 2023, 17:00 |
| SNDX | Syndax Pharmaceuticals Inc | 02 Feb 2023 | 1 | +$485,350 | 4 | Chief Accounting Officer | 03 Feb 2023, 15:58 |
| SNDX | Syndax Pharmaceuticals Inc | 01 Feb 2022 | 3 | +$469,576 | 4 | Chief Accounting Officer | 03 Feb 2022, 16:31 |
| SNDX | Syndax Pharmaceuticals Inc | 22 Oct 2021 | 0 | $0 | 3 | Chief Accounting Officer | 04 Nov 2021, 16:03 |